Eagle Pharmaceuticals announces fifth Orange Book listed patent for Ryanodex
Eagle Pharmaceuticals announced that the company has been issued a new patent related to its RYANODEX product by the United States Patent and Trademark Office. Patent number 9,884,044 will expire June 2022. The USPTO has now issued or allowed a total of seven patents in the RYANODEX family of patents expiring between 2022 and 2025. The newly issued patent will be listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations. RYANODEX is approved and marketed for the treatment of malignant hyperthermia and for the prevention of malignant hyperthermia in patients at high risk. Eagle is currently investigating RYANODEX as a potential treatment of multiple additional indications including exertional heat stroke, MDMA and methamphetamine intoxication, and nerve agent exposure.